Evidence map›Paper›PMID 32484516›Full record

ReviewBriefings in bioinformatics2021

Scoring functions for drug-effect similarity.

Stephan Struckmann, Mathias Ernst, Sarah Fischer, Nancy Mah, Georg Fuellen, Steffen Möller

Open access · hybridAbstract readReview
In one paragraph

Review in Briefings in bioinformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Stephan StruckmannIBIMA, Rostock University Medical Center, Rostock, 18041, Germany.ORCID 0000-0002-8565-7962
Mathias ErnstIBIMA, Rostock University Medical Center, Rostock, 18041, Germany.ORCID 0000-0003-1096-4316
Sarah FischerIBIMA, Rostock University Medical Center, Rostock, 18041, Germany.ORCID 0000-0002-6218-7275
Nancy MahBCRT - Berlin Institute of Health Center for Regenerative Therapies, Charité - University Medicine Berlin, 13353, Germany.ORCID 0000-0002-1240-8076
Georg FuellenIBIMA, Rostock University Medical Center, Rostock, 18041, Germany.ORCID 0000-0002-4994-9829
Steffen MöllerIBIMA, Rostock University Medical Center, Rostock, 18041, Germany.ORCID 0000-0002-7187-4683
University of Rostock · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversitätsmedizin Greifswald · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

motivationThe difficulty to find new drugs and bring them to the market has led to an increased interest to find new applications for known compounds. Biological samples from many disease contexts have been extensively profiled by transcriptomics, and, intuitively, this motivates to search for compounds with a reversing effect on the expression of characteristic disease genes. However, disease effects may be cell line-specific and also depend on other factors, such as genetics and environment. Transcription profile changes between healthy and diseased cells relate in complex ways to profile changes gathered from cell lines upon stimulation with a drug. Despite these differences, we expect that there will be some similarity in the gene regulatory networks at play in both situations. The challenge is to match transcriptomes for both diseases and drugs alike, even though the exact molecular pathology/pharmacogenomics may not be known.

resultsWe substitute the challenge to match a drug effect to a disease effect with the challenge to match a drug effect to the effect of the same drug at another concentration or in another cell line. This is welldefined, reproducible in vitro and in silico and extendable with external data. Based on the Connectivity Map (CMap) dataset, we combined 26 different similarity scores with six different heuristics to reduce the number of genes in the model. Such gene filters may also utilize external knowledge e.g. from biological networks. We found that no similarity score always outperforms all others for all drugs, but the Pearson correlation finds the same drug with the highest reliability. Results are improved by filtering for highly expressed genes and to a lesser degree for genes with large fold changes. Also a network-based reduction of contributing transcripts was beneficial, here implemented by the FocusHeuristics. We found no drop in prediction accuracy when reducing the whole transcriptome to the set of 1000 landmark genes of the CMap's successor project Library of Integrated Network-based Cellular Signatures. All source code to re-analyze and extend the CMap data, the source code of heuristics, filters and their evaluation are available to propel the development of new methods for drug repurposing. AVAILABILITY: https://bitbucket.org/ibima/moldrugeffectsdb. CONTACT: steffen.moeller@uni-rostock.de. SUPPLEMENTARY INFORMATION: Supplementary data are available at Briefings in Bioinformatics online.

Indexed as

Drug RepositioningPharmacogeneticsComputational BiologyGene Expression ProfilingGene Regulatory NetworksReproducibility of ResultsStructure-Activity RelationshipTranscriptomedrug repositioningdrug repurposingevaluationtranscriptomics

Identifiers

PMID32484516
PMCPMC8138836
OpenAlexW3032071647

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.